

GRANTS AND CONTRACTS

■ **CENTER FOR INHERITED DISEASE RESEARCH (CIDR) HIGH THROUGHPUT GENOTYPING RESOURCE ACCESS (X01): PAR-08-258**

Components of Participating Organizations

This is an NIH-wide initiative that is being administered by NHGRI on behalf of NIH.

Application Due Date(s): November 3, 2008; March 2, 2009; July 1, 2009; November 2, 2009; March 2, 2010; July 1, 2010; November 1, 2010; March 1, 2011; July 1, 2011

Earliest Anticipated Start Date(s): March 1, 2009 ; July 1, 2009; December 1, 2009; March 1, 2010; July 1, 2010; December 1, 2010; March 1, 2011; July 1, 2011; December 1, 2011

Expiration Date: July 2, 2011

CIDR high-throughput genotyping and supporting statistical genetics services are designed to aid investigations seeking to identify genes that contribute to human health and disease. The services provided through CIDR concentrate primarily on multi-factorial hereditary disease, but other types of projects can also be accommodated. CIDR provides the most up-to-date genotyping platforms and services. This is an NIH-wide initiative that is being managed by NHGRI. Information about the current services offered can be accessed via: <http://www.cidr.jhmi.edu>.

This FOA will utilize the X01 grant mechanism. There are no funds associated with a resource access award. However, the NIH does support the genotyping done through its funding of CIDR. Applicants must get prior approval from an NIH supporting institute (<http://www.cidr.jhmi.edu>) or otherwise explain how the genotyping will be supported. The applications will be coded X01s. There are no dollars associated with these requests and receipt of access does not result in funds being awarded to the applicant. The total number of projects granted CIDR access is dependent on the number of meritorious applications and the availability of resources at CIDR. The project period is up to 5 years.

Eligible Project Directors/Principal Investigators (PDs/Pis). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. More than one PD/PI (i.e., multiple PDs/Pis) may be designated on the application. Applicants may

submit more than one application, provided that each application is scientifically distinct. Applicants may resubmit for projects that are denied access, but they must include a one page introduction addressing the previous peer review. Up to 2 resubmission applications will be accepted. Applicants may submit a renewal application. Continuation projects must be submitted as a new application with explanation. This FOA uses non-standard due dates.

■ **EXPLORATORY STUDIES IN CANCER DETECTION, DIAGNOSIS, AND PROGNOSIS (R21): PA-08-267**

Components of Participating Organizations
National Cancer Institute

This funding opportunity announcement (FOA) is a re-issue of PA-06-299.

Opening Date: January 16, 2009

Letters of Intent Receipt Date(s): Not Applicable

Application Submission/Receipt Dates: Standard dates apply

This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), invites grant applications from institutions and organizations that are interested in developing and testing innovative methods in cancer detection, diagnosis, and prognosis. The NCI is especially interested in research studies that focus on the development and testing of improved methods for detecting specific characteristics of cancer, which can be subsequently used for the clinical management of cancer patients or individuals who are at risk for (developing) cancer. It is important that research studies focus on the search for molecular and cellular differences between tumors, pre-malignant, or normal tissues. The studies should determine the clinical translational significance of these differences by correlation with clinical parameters, in order to answer clinical problems related to detection, diagnosis, treatment, and prognosis.

This FOA utilizes the NIH Exploratory/Developmental Grant (R21) mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known. The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to \$275,000 over an R21 two-year period, with no more than \$200,000 in direct costs allowed in any single

year. The R21 application Research Plan component of the PHS398 (Items 2–5) may not exceed 15 pages, including tables, graphs, figures, diagrams, and charts. For information on NIH Exploratory/Developmental Research Grant Award (R21) see http://grants1.nih.gov/grants/funding/funding_program.htm.

Eligible Project Directors/Principal Investigators (PDs/Pis) include Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. More than one PD/PI (i.e., multiple PDs/Pis), may be designated on the application. Applicants may submit more than one application, provided that each application is scientifically distinct. Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement). The R21 is not renewable.

■ ANCILLARY STUDIES IN IMMUNOMODULATION CLINICAL TRIALS (R01): RFA-AI-08-011

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Neurological Disorders and Stroke
National Institute of Diabetes and Digestive and Kidney Diseases

Release/Posted Date: August 27, 2008

Opening Date: October 10, 2008

Letters of Intent Receipt Date(s): Thirty days prior to application receipt date

Application Due Date(s): Initial due date November 9, 2008, applications will be accepted MONTHLY on the ninth of each month. Applications which are received after the ninth automatically will be processed the following month.

Earliest Anticipated Start Date(s): Thirteen weeks after receipt date

Expiration Date: June 10, 2009

Purpose. This FOA invites R01 applications for mechanistic studies in clinical trials of: (1) immunomodulatory interventions for immune system mediated diseases, including, but not limited to: asthma and allergic diseases; graft rejection in solid organ, cell, and tissue transplantation; graft versus host disease in hematopoietic stem cell transplantation; and chronic inflammatory, au-

toimmune, and immunodeficiency diseases; and (2) preventative and therapeutic, vaccines for non-HIV/AIDS infectious diseases, including NIAID Category A, B, and C agents of bioterrorism and emerging/re-emerging infectious diseases. This FOA is a renewal with modifications of RFA AI-05-028 (<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-05-028.html>). In order to review and confer awards to grant applications received in response to this FOA in a timely fashion, without delay of the parent clinical trial, applications submitted in response to the FOA will be subject to an accelerated review/award process. Highly meritorious applications selected for funding under this FOA may receive their awards as early as thirteen weeks after the application receipt date. Holidays and other circumstances may alter this schedule slightly.

Mechanism of Support. This FOA will utilize the NIH Research Project grant (R01) mechanism.

Funds Available and Anticipated Number of Awards. The National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), of the National Institutes of Health (NIH) intend to commit \$2 million in Fiscal Year 2009 to fund five to six applications. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Budget and Project Period. Applicants may request up to \$250,000 direct costs (excluding third party F&A costs) per year and a project period of up to 4 years.

Application Research Plan Component Length. The R01 application Research Plan component of the PHS 398 (Items 2–5) may not exceed 15 pages, including tables, graphs, figures, diagrams, and charts (go to http://grants.nih.gov/grants/funding/funding_program.htm).

Eligible Project Directors/Principal Investigators (PDs/Pis). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Number of PDs/Pis. More than one PD/PI (i.e., multiple PDs/Pis) may be designated on the application.

Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct.

Resubmissions. Resubmission applications are not permitted

Renewals. Renewal applications are not permitted in response to this FOA.

■ **INNOVATIVE APPROACHES TO TARGET IDENTIFICATION AND ASSAY DEVELOPMENT FOR FUNGAL DIAGNOSIS (R21/R33): RFA-AI-08-055**

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases

Opening Date: December 15, 2008

Letters of Intent Receipt Date(s): January 12, 2009

Application Due Date(s): February 11, 2009

Earliest Anticipated Start Date(s): December 2009

Expiration Date: February 12, 2009

Purpose. This Funding Opportunity Announcement (FOA), titled Innovative Approaches to Target Identification and Assay Development for Fungal Diagnosis, and issued by the NIAID, National Institutes of Health, solicits applications to foster collaborative efforts between the mycology research community and the innovative technology sector to develop novel clinical diagnostic targets and subsequent assays for invasive aspergillosis (IA) and other invasive fungal diseases common to immunocompromised or immunosuppressed patients. Ultimately, research sponsored in response to this FOA should lead to the development of a novel diagnostic test(s) for detection of invasive fungal disease(s) that must include invasive aspergillosis.

Mechanism of Support. This FOA will utilize the NIH R21/R33 Phased Innovation Award to support innovative exploratory and developmental research. Under the R21 phase, research is initiated and carried out through a milestone-driven process to establish the feasibility of new diagnostics, diagnostic strategies and support technologies. The R33 phase then provides the support required to translate the innovation discoveries into the preclinical/clinical development pipeline.

Funds Available and Anticipated Number of Awards. The total amount of funding that the NIAID intends to commit to this announcement is \$1.5 million in FY 2010 to fund five to seven grants. Funding will be based on scientific and technical merit, program priorities, and availability of funds. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.

Budget and Project Period. The total project period for an application submitted in response to this FOA cannot exceed five years. Awards will support milestone-driven exploratory/feasibility “proof-of-concept” studies (two-year R21 phase), with possible rapid transition to expanded development (three-year R33 phase). Support for the R21 phase cannot exceed two years and direct costs are limited to \$275,000 over the R21 two-year period, with a maximum of \$200,000 in direct costs allowed in any single year. The R33 award phase is limited to \$300,000 in direct costs per year and cannot exceed three years. The NIAID anticipates that a maximum of fifty percent (50%) of the funded R21 phase awards will progress to the R33 award.

Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/ organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs) may be designated on the application.

Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct.

Resubmissions. Resubmission applications are not permitted in response to this FOA.

Renewals. Renewal applications are not permitted in response to this FOA.

■ **DRUG ABUSE EPIDEMIOLOGY AND SERVICES RESEARCH IN COOPERATION WITH THE CLINICAL AND TRANSLATIONAL SCIENCE AWARDS CONSORTIUM (R01): PAS-09-001**

Components of Participating Organizations

National Institute on Drug Abuse

Opening Date: January 5, 2009

Letters of Intent Receipt Date(s): Not required

Expiration Date: January 8, 2012

Purpose. Through this program announcement with set aside (PAS), the National Institute on Drug Abuse (NIDA) invites applicants to develop innovative drug abuse epidemiology or health services research in cooperation with academic centers supported through the NIH Clinical and Translational Science Awards (CTSA) consortium. A major NIH initiative, the CTSA consortium

is transforming how clinical and translational research is conducted, building an infrastructure for multidisciplinary researchers and clinicians to perform research and develop new treatments more efficiently. As a part of this infrastructure, CTSA sites have established partnerships with a range of clinical settings and have access to large, multi-generational population cohorts. These features of the CTSA sites offer a unique opportunity for researchers to integrate drug abuse epidemiology and health services research in these settings. Applicants are asked to propose innovative drug abuse research which builds upon the resources available at CTSA sites, resources which would include CTSA efforts to strengthen networks of clinical sites and to establish innovative information technologies, phenotyping systems, and bio-banks. A broad range of drug abuse epidemiology and health services research areas will be supported under the auspices of this FOA, as described below.

Mechanism of Support. This FOA will utilize the R01 grant mechanism.

Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 4 to 8 projects awarded as a result of this announcement is \$2 million for fiscal year 2009 and \$2 million for fiscal year 2010. Future year amounts will depend on annual appropriations. The total amount awarded and the number of awards will depend upon the number, quality, duration, and cost of the applications received. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Budget and Project Period. Budgets for direct costs of up to \$500,000 per year (exclusive of associated indirect costs) and a project duration of up to five years may be requested. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the numbers, quality, duration, and costs of the applications received.

Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs) may be designated on the application.

Number of Applications. Applicants may submit more than one application, provided that each application is scientifically distinct.

Resubmissions. Applicants may submit a resubmission application, but such an application must include an introduction addressing the previous peer review critique (Summary Statement).

Renewals. Applicants may submit a renewal application.

■ REPLICATION AND FINE-MAPPING STUDIES FOR THE GENES ENVIRONMENT AND HEALTH INITIATIVE (GEI)(R01): RFA-CA-09-003

Components of Participating Organizations

This FOA is developed as a part of the NIH-wide Genes, Environment, and Health Initiative (GEI). All NIH Institutes and Centers participate in NIH-wide initiatives.

This FOA will be administered by the National Cancer Institute

Release/Posted Date: September 30, 2008

Letters of Intent Receipt Date(s): October 24, 2008

Application Due Date(s): December 1, 2008

Earliest Anticipated Start Date(s): July 2009

Expiration Date: December 2, 2008

Purpose. This funding opportunity announcement (FOA), administered by the National Cancer Institute, is a part of the Genes, Environment, and Health Initiative (GEI, <http://www.gei.nih.gov/>) sponsored by the National Institutes of Health (NIH). The purpose of this FOA is to provide support for replication and fine-mapping studies of genetic regions that are putatively associated with common complex traits, primarily those identified by genome-wide association studies (GWAS). The proposed projects should aim to enhance the identification of causal variants influencing complex diseases. Any phenotype may be appropriate for these projects (i.e., studies need not be oriented on cancer or cancer-related phenotypes). This FOA will not support recruitment of human subjects, collection of human specimens, collection of medical or phenotype data, studies using animal models, or discovery genome-wide association efforts.

Mechanism of Support. This FOA will utilize the NIH research project (R01) grant mechanism.

Funds Available and Anticipated Number of Awards. The NCI has set aside \$2 million in Fiscal Year 2009 for 4–6 awards under this FOA.

Budget and Project Period: Budget requests must not exceed \$400,000 in total costs (including genotyping

costs). The complete project period must not exceed 12 months.

Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs) may be designated on the application.

Number of Applications. Applicants may submit more than one application, provided that each application is scientifically distinct.

Resubmissions. Resubmission applications are not permitted in response to this FOA.

Renewals. Renewal applications are not permitted in response to this FOA.

■ ANCILLARY STUDIES IN CLINICAL TRIALS (R01): RFA-HL-09-001

Components of Participating Organizations

National Heart, Lung, and Blood Institute

Release/Posted Date: August 11, 2008

Letters of Intent Receipt Date(s): December 30, 2008; April 29, 2009; August 31, 2009

Application Due Date(s): January 30, 2009; May 29, 2009; September 30, 2009

Earliest Anticipated Start Date(s): July 1, 2009; December 1, 2009; March 1, 2010

Expiration Date: October 1, 2009

Purpose. The purpose of this Funding Opportunity Announcement (FOA) is to solicit research grant applications to conduct time-sensitive ancillary studies related to heart, lung, and blood diseases and sleep disorders in conjunction with ongoing NIH- or non-NIH-supported clinical trials.

Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) grant mechanism.

Funds Available and Anticipated Number of Awards. The NHLBI intends to commit approximately \$1.6 million in FY 2009 to fund 4–5 new grants and \$3.2 million in FY 2010 to fund 8–9 new grants under this FOA. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Budget and Project Period. An applicant may request a project period of up to four years and a budget for direct costs up to \$250,000 (10 modules) per year.

Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/ organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs) may be designated on the application.

Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct.

Renewals. Renewal applications are not permitted in response to this FOA.

Special Date(s). This FOA uses non-standard due dates. See Receipt, Review and Anticipated Start Dates.

■ BASIC HIV VACCINE DISCOVERY RESEARCH (R01): RFA-AI-08-053

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases

Release/Posted Date: August 27, 2008

Opening Date: December 15, 2008

Letters of Intent Receipt Date(s): December 5, 2008

Application Due Date(s): January 5, 2009

Earliest Anticipated Start Date(s): July, 2009

Expiration Date: January 6, 2009

Purpose. The aim of this Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), is to stimulate the discovery of an effective prophylactic HIV vaccine by soliciting Research Project Grant (R01) applications for hypothesis-driven basic research in HIV/AIDS, and general virology and immunology that is focused on directly achieving that aim. The emphasis is on discovery research, including the identification of new concepts and approaches that will inform the design of an optimal prophylactic HIV vaccine design, and the implementation of concepts and/or approaches employed successfully in the development of vaccines for other infections.

Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism.

Funds Available and Anticipated Number of Awards. NIAID intends to commit approximately \$10M in total costs in FY 2009 to fund 20–30 applications submitted in response to this FOA. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Budget and Project Period. Budgets may be submitted for direct costs of up to \$350,000 per year, or up to \$500,000 in any year(s) when non human primate studies are involved. Project duration may be up to five years.

Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skill, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/ organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs) may be designated on the application.

Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct.

■ SUMMER INSTITUTE FOR TRAINING IN BIOSTATISTICS II (T15): RFA-HL-09-009

Components of Participating Organizations

*National Heart, Lung, and Blood Institute
National Center for Research Resources*

Release Date: September 3, 2008

Letters of Intent Receipt Date: December 5, 2008

Application Receipt Date: January 6, 2009

Earliest Anticipated Start Date: July 1, 2009

Expiration Date: January 7, 2009

The National Heart, Lung and Blood Institute (NHLBI) and the National Center for Research Resources (NCRR) invite applications for training grants to develop, conduct, and evaluate summer courses in the basic principles and methods of biostatistics as employed in biomedical research. The courses will introduce advanced undergraduate students and beginning graduate students to the field of biostatistics for the purpose of encouraging them to pursue careers in biostatistics. The courses will cover the fundamental concepts of probability, statistical reasoning and inferential methods motivated, in part, by examples that include data collected in studies of heart, lung, blood, and sleep disorders. The courses will be taught during the summers of 2010, 2011, 2012 with

appropriate modifications or refinements following each of the first two summer sessions.

Mechanism of Support. This FOA will use the NIH Continuing Education Training Grant award mechanism (T15). As an applicant you will be solely responsible for planning, directing, and executing the proposed project.

Funds Available and Anticipated Number of Awards. The NHLBI and NCRR intend to fund up to seven grants in response to this FOA, with total amount of funding up to \$1,739,000 for fiscal year 2009.

Budget and Project Period. The total project period for an application submitted in response to this funding opportunity may not exceed three years. Direct costs are limited to \$248,000 per year for a three-year period. Because the nature and scope of the proposed research will vary from application to application, the size and duration of each award may also vary. Although the financial plans of the NHLBI provide support for this program, awards pursuant to this FOA are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications.

Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs) may be designated on the application.

Number of Applications. Applicants may submit more than one application, provided they are scientifically distinct.

Resubmissions. Resubmission applications are not permitted in response to this FOA.

■ BIOSIGNATURES OF CHRONIC DRUG EXPOSURE (R21): RFA-DA-09-022

Components of Participating Organizations

National Institute on Drug Abuse

Release/Posted Date: October 1, 2008

Opening Date: December 27, 2008

Letters of Intent Receipt Date(s): December 29, 2008

Application Due Date(s): January 27, 2009

Earliest Anticipated Start Date(s): September 2009

Expiration Date: January 28, 2009

In relation to this FOA, biosignatures are defined as biological indicators obtainable through assays, which can be used to ascertain facts about an individual's past exposure to drugs of abuse. Biosignature could be comprised of more than one biomarker. The total number of biomarkers must be reasonably limited to address the developability of the screening assay. This FOA would support high risk projects to search for peripheral, not associated with the central nervous system, biosignatures (not drug or drug metabolites) that could serve as surrogates to monitor changes that are taking place in the brain in response to illicit and licit drug exposure, withdrawal or relapse. These projects are intended to be feasibility projects using animal models only to identify appropriate clinically accessible biomaterial (e.g., blood, lymphocytes, bladder epithelial cells, stem cells) and to identify the best class or classes of molecules (proteins, peptides, RNA, miRNA, etc.) suitable for assay development. These feasibility projects are intended to address technical issues such as sensitivity and signal-to-noise ratio, in addition to predictive validity.

Mechanism of Support. This FOA will utilize the R21 grant mechanism, as The National Institute on Drug Abuse recognizes the high risk nature of this project. Funds Available and Anticipated Number of Awards. The total amount of funding that the NIDA expects to award through this announcement is \$2,000,000 for an anticipated 5–7 awards.

Budget and Project Period. Budgets for direct costs of up to \$200,000 per year and a project duration of up to three years may be requested for a maximum of \$400,000 direct costs over a three-year project period.

Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/ organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs) may be designated on the application.

Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct.

Resubmissions. Resubmission applications are not permitted in response to this FOA.

Renewals. Renewal applications are not permitted in response to this FOA.

■ THE ROLE OF CARDIOMYOCYTE MITOCHONDRIA IN HEART DISEASE: AN INTEGRATED APPROACH (R01): RFA-HL-10-002

Components of Participating Organizations *National Heart, Lung, and Blood Institute*

Release/Posted Date: September 26, 2008

Open Date: April 20, 2009

Letters of Intent Receipt Date(s): April 20, 2009

Application Due Date(s): May 19, 2009

Earliest Anticipated Start Date(s): April, 2010

Expiration Date: May 20, 2009

The National Heart, Lung, and Blood Institute (NHLBI) invites applications for collaborative research projects to develop an integrated understanding of cardiomyocyte mitochondria and its contributions to myocardial adaptations and heart disease progression by combining functional data with information derived from powerful new technologies.

Mechanism of Support. This FOA will utilize the R01 grant mechanism.

Funds Available and Anticipated Number of Awards. The NHLBI intends to commit approximately \$4 million in total costs in FY2010, and up to \$16 million over four years, to fund up to six grants under this FOA. Awards issued under this FOA are contingent upon availability of funds and the submission of a sufficient number of meritorious applications.

Budget and Project Period. Budgets for direct costs of up to \$500,000 per year and a project duration of up to four years may be requested for a maximum of \$2,000,000 direct costs over a four-year project period. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the numbers, quality, duration, and costs of the applications received.

Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs) may be designated on the application.

Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct.